Sara M Tolaney
Overview
Explore the profile of Sara M Tolaney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
294
Citations
10331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Felsheim B, Fernandez-Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):24.
PMID: 40057511
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage...
2.
Rugo H, Schmid P, Tolaney S, Marme F, Bardia A, Spears P, et al.
Future Oncol
. 2025 Mar;
21(7):775-786.
PMID: 40045471
No abstract available.
3.
Grinda T, Morganti S, Hsu L, Yoo T, Kusmick R, Aizer A, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):22.
PMID: 40038301
Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in...
4.
Hamilton E, Loibl S, Bachelot T, Gnant M, Niikura N, Park Y, et al.
Future Oncol
. 2025 Feb;
21(7):795-806.
PMID: 40017004
Novel selective estrogen receptor degraders (SERDs) are a promising therapeutic option under investigation for patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The efficacy of...
5.
Garrido-Castro A, Graham N, Ali L, Herold C, Desrosiers J, Do K, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010764
Background: Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in...
6.
McArthur H, Tolaney S, Dent R, Schmid P, Asselah J, Liu Q, et al.
Ther Adv Med Oncol
. 2025 Feb;
17:17588359251316176.
PMID: 39917260
Background: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) and hormone receptor (HR)-low/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, treatments that improve clinical outcomes while...
7.
Goel S, Jovanovic B, Chu X, Hughes M, Erick T, Russo D, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39908010
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in hormone receptor-positive metastatic breast cancer patients. However, their activity has been relatively...
8.
Tolaney S, Cardillo T, Chou C, Dornan C, Faris M
Clin Cancer Res
. 2025 Feb;
PMID: 39903492
Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is currently approved to treat metastatic triple-negative breast cancer and HR+/HER2- breast cancer, and is under clinical investigation for a range of other...
9.
Trapani D, Jin Q, Miller K, Rugo H, Reeder-Hayes K, Traina T, et al.
Clin Breast Cancer
. 2025 Jan;
PMID: 39890560
Background: Breast cancer patients with residual disease after neoadjuvant therapy have increased risk of recurrence. Novel therapies to decrease this risk are urgently needed. Methods: Two clinical trials (05-055 and...
10.
Waks A, Tarantino P, Chen E, Freedman R, Lin N, Tayob N, et al.
Cancer
. 2025 Jan;
131(3):e35729.
PMID: 39887682
Background: The risk of recurrence in patients with small, lymph node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancers untreated with adjuvant chemotherapy/HER2-directed therapy is uncertain. To investigate this,...